These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7965486)

  • 1. Neonatal infection does not affect the immunoreactive trypsinogen screening test for cystic fibrosis.
    Wilson DC; Leslie H; Edgar JD; Halliday HL; Dodge JA
    J Pediatr Gastroenterol Nutr; 1994 Jul; 19(1):97-9. PubMed ID: 7965486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels.
    Rock MJ; Mischler EH; Farrell PM; Wei LJ; Bruns WT; Hassemer DJ; Laessig RH
    Pediatrics; 1990 Jun; 85(6):1001-7. PubMed ID: 2187173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
    Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF
    Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis.
    Ranieri E; Ryall RG; Morris CP; Nelson PV; Carey WF; Pollard AC; Robertson EF
    BMJ; 1991 May; 302(6787):1237-40. PubMed ID: 2043846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations.
    Hammond KB; Abman SH; Sokol RJ; Accurso FJ
    N Engl J Med; 1991 Sep; 325(11):769-74. PubMed ID: 1870650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
    Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
    J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with a false-positive screening test.
    Rock MJ; Mischler EH; Farrell PM; Bruns WT; Hassemer DJ; Laessig RH
    Pediatr Pulmonol; 1989; 6(1):42-8. PubMed ID: 2704582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.
    Castellani C; Picci L; Scarpa M; Dechecchi MC; Zanolla L; Assael BM; Zacchello F
    Am J Med Genet A; 2005 Jun; 135(2):142-4. PubMed ID: 15832355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystic fibrosis newborn screening: impact on reproductive behavior and implications for genetic counseling.
    Mischler EH; Wilfond BS; Fost N; Laxova A; Reiser C; Sauer CM; Makholm LM; Shen G; Feenan L; McCarthy C; Farrell PM
    Pediatrics; 1998 Jul; 102(1 Pt 1):44-52. PubMed ID: 9651412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations.
    Sommerburg O; Krulisova V; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Votava F; Balascakova M; Skalicka V; Stopsack M; Gahr M; Macek M; Mall MA; Hoffmann GF
    J Cyst Fibros; 2014 Jan; 13(1):15-23. PubMed ID: 23891278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Quantase neonatal immunoreactive trypsinogen (IRT) screening assay for cystic fibrosis.
    Ball CL; Montgomery MD; Bridge PJ; Lyon ME
    Clin Chem Lab Med; 2005; 43(5):570-2. PubMed ID: 15899682
    [No Abstract]   [Full Text] [Related]  

  • 12. Cystic fibrosis screening by dried blood spot trypsin assay: results in 75,000 newborn infants.
    Wilcken B; Brown AR; Urwin R; Brown DA
    J Pediatr; 1983 Mar; 102(3):383-7. PubMed ID: 6827410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
    Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
    J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial regional evaluation of the Cystic Fibrosis Newborn Screening Program: data from the Mediterranean coast of Turkey.
    Başaran AE; Başaran A; Kocacik DF; Alper Ö; Acican D; Bingöl A
    Turk J Med Sci; 2019 Dec; 49(6):1655-1661. PubMed ID: 31655510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis.
    Sarles J; Barthellemy S; Férec C; Iovanna J; Roussey M; Farriaux JP; Toutain A; Berthelot J; Maurin N; Codet JP; Berthézène P; Dagorn JC
    Arch Dis Child Fetal Neonatal Ed; 1999 Mar; 80(2):F118-22. PubMed ID: 10325788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
    Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
    J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk calculations for cystic fibrosis in neonatal screening by immunoreactive trypsinogen and CFTR mutation tests.
    Ogino S; Flodman P; Wilson RB; Gold B; Grody WW
    Genet Med; 2005; 7(5):317-27. PubMed ID: 15915083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neonatal screening for cystic fibrosis: result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analyses.
    Férec C; Verlingue C; Parent P; Morin JF; Codet JP; Rault G; Dagorne M; Lemoigne A; Journel H; Roussey M
    Hum Genet; 1995 Nov; 96(5):542-8. PubMed ID: 8530001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study for cystic fibrosis neonatal screening: the Cuban experience.
    Castells EM; Sánchez A; Frómeta A; Mokdse Y; Ozunas N; Licourt T; Arteaga AL; Silva E; Collazo T; Rodríguez F; Martín O; Espinosa M; Del Río L; Pérez PL; Morejón G; Almira C; Núñez Z; Melchor A; González EC
    Clin Chem Lab Med; 2020 Oct; 58(11):1857-1864. PubMed ID: 32352395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
    Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
    Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.